Sunday, January 29, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Chemical Threat Medical Countermeasure Development

by Global Biodefense Staff
February 27, 2017
BAA Broad Agency Announcements

The Biomedical Advanced Research and Development Authority (BARDA) has updated a funding mechanism for advanced development of chemical threat medical countermeasures.

This effort is part of a multi-year, multi-topic Broad Agency Announcement (BAA) for the Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasures for BARDA.

Proposals are sought for medical countermeasures that treat the acute health effects of chemical threats, are easy to administer in a mass-casualty situation, and are rapidly effective as post-exposure therapies.

Candidates should have demonstrated in vivo activity and potential for efficacy; and have held a pre-IND meeting with the FDA for licensure as an MCM prior to the submission of a white paper to the BARDA BAA.

Specific areas of interest include:

  • Pulmonary Agents to prevent and treat lung damage resulting from exposure to agents such as
  • chlorine and phosgene.
  • Vesicants that limit harmful aspects of exposure to vesicating agents such as sulfur mustard and Lewisite.
  • Blood/Metabolic Agents to treat acute poisoning from agents such as cyanides. Antidotes should be easily administered by first responders in personal protective equipment.
  • Nerve Agents and OP Pesticides: Development of MCMs to treat seizures that are refractory to treatment with benzodiazepines.
  • Novel MCM Delivery Mechanisms

BARDA notes that preference will be given to drug candidates that are already approved or are in clinical development for a conventional indication similar to that arising from exposure to a chemical agent.

Further details are available via Solicitation Number: BAA-16-100-SOL-00001.

Tags: ASPRBAABARDAChemical WeaponsHHS

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC